News | Cardiovascular Ultrasound | June 15, 2022

Cardiawave Confirms the Safety of VALVOSOFT its Non-Invasive Ultrasound Treatment for Aortic Stenosis

Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking

Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.

This final phase of the clinical study “Valvosoft FIM STUDY” (FIM II) showed no signs of any cerebral vascular anomaly in the 10 patients treated. This marks the completion of two successful First-In-Human clinical studies involving a total of 40 patients treated in France, the Netherlands and Serbia.

“This confirmation of the safety of Valvosoft bodes well for the launch of patient recruitment for our European pivotal study which will commence shortly in France, and extended to Germany and the Netherlands, with the aim of obtaining CE Marking.” said Benjamin Bertrand, CEO of Cardiawave.

Valvosoft’s non-invasive treatment brings great hope for patients with aortic stenosis and for their families. Having the absence of any abnormality before and after treatment being confirmed by MRI scans is major clinical step forward” declared Professeur Emmanuel Messas the Georges Pompidou European Hospital (AP-HP), in Paris.

For more information: www.cardiawave.com

 


Related Content

News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
News | Cardiovascular Ultrasound

July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial ...

Home July 27, 2023
Home
Feature | Cardiovascular Ultrasound

February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement ...

Home February 10, 2023
Home
Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to ...

Home July 07, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased ...

Home June 14, 2022
Home
Subscribe Now